Bolt Biotherapeutics (BOLT) Q3 2024 earnings summary

Executive summary

• Focus shifted to BDC-3042 (Dectin-2 agonist antibody) and next-gen ISAC platform, discontinuing trastuzumab imbotolimod and reducing workforce by 50% to lower expenses.

• BDC-3042 advanced to highest dose level in Phase 1 for advanced cancers; data update expected H1 2025.

• BDC-4182, targeting Claudin 18.2, showed strong preclinical activity and is on track for clinical trials in 2025.

• Collaborations with Genmab and Toray progressing; pipeline includes multiple solid tumor indications.

• Revenue is solely from collaborations; no product sales to date.

Financial highlights

• Q3 2024 collaboration revenue was $1.1M, down from $2.5M in Q3 2023; nine-month revenue rose to $7.7M from $5.8M year-over-year.

• Q3 2024 R&D expenses were $13.8M (down $1.2M year-over-year); nine-month R&D expenses were $45.7M (up $0.5M year-over-year).

• General and administrative expenses fell to $3.8M in Q3 2024 (down $2.0M year-over-year); nine-month G&A expenses were $14.5M (down $2.5M year-over-year).

• Net loss for Q3 2024 was $15.2M, or $(0.40) per share; nine-month net loss was $47.2M, or $(1.24) per share.

• Cash, cash equivalents, and marketable securities totaled $84.4M as of September 30, 2024.

Outlook and guidance

• Cash and investments expected to fund operations and milestones through mid-2026.

• Additional capital will be needed to advance programs beyond current runway.

• BDC-4182 clinical trial initiation planned for Q2 2025; BDC-3042 Phase 1 data update expected in H1 2025.